Precigen Inc. (NASDAQ:PGEN) does about 768.51K shares in volume on a normal day but saw 1690582 shares change hands in Monday trading. The company now has a market cap of 438.04M USD. Its current market price is $2.17, marking an increase of 9.05% compared to the previous close of $1.99. The 52 week high reached by this stock is $3.04 whilst the lowest price level in 52 weeks is $1.12. The script in recent trading has seen the stock touch a high of $2.288 and a low of $2.0125.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Precigen Inc. (PGEN) has a 20-day trading average at $1.6700 and the current price is -28.62% off the 52-week high compared with 93.75% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.7100 and its 200-day simple moving average is $1.7700. If we look at the stock’s price movements over the week, volatility stands at 10.17%, which decreases to 8.74% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 68.99 to suggest the stock is neutral.
4 analysts observing the Precigen Inc. (PGEN) stock have set the 12-month price targets for the company’s shares at between $4.20 and $14.00. The consensus objective for the share price is $7.80, suggesting that the stock has a potential upside of 72.18% over the period. The median price target is 66.62% away from the current levels at $6.50.
FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 18, 2022 when Cantor Fitzgerald initiated the stock to “Overweight” and issued a price target of $7. Wells Fargo initiated its price target at $14.
The current price level is 32.84%, 27.78%, and 22.82% away from its SMA20, SMA50, and SMA200 respectively, with the PGEN price moving below the 50-day SMA on January 23. Precigen Inc. (PGEN) stock is up 7.96% over the week and 45.64% over the past month. Its price is 42.76% year-to-date and -26.69% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.09 above consensus estimates by $0.04. The company’s next earnings report is expected on 05/10/2023, with forecasts estimating quarterly EPS at $0.02 and -$0.43 for whole year. PGEN’s earnings per share are forecast to grow by 8.50% this year and -23.30% over next year. Expected sales for next quarter are $2.99 million, which analysts say will come at $73.21 million for the current fiscal year and next year at $22.03 million. In addition, estimates put the company’s current quarterly revenue at an average of $35.31 million.
To reach the target analysts have set, the stock logically needs to grow 72.18 percent from here.
Outstanding shares total 200.67M with insiders holding 11.90% of the shares and institutional holders owning 66.35% of the company’s common stock. The company has a return on investment of -27.30% and return on equity of 26.80%. The beta has a value of 1.90. Price to book ratio is 3.06 and price to sales ratio is 8.87.
Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by iShares Russell 2000 ETF, which sold off 23973.0 shares to end up with 2,295,089 shares worth $3.49 million. JPMorgan Funds – Thematics – Gene cut their holdings by -7.65% in the company over the course of the most recent quarter. It now holds a 0.79% position in Precigen Inc. thanks to 1.65 million shares amounting to $2.51 million.
